TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Practical Application, Acceptability and Effectiveness of a Portfolio Diet in Reducing Serum Cholesterol
Brief Summary: The purpose of this trial is to re-evaluate the potential role of diet in modulating cardiovascular risk factors. If potent lipid-lowering effects through novel dietary interventions can be demonstrated, then diet may again be seen as providing an alternative to drug therapy in the primary prevention of cardiovascular disease.

Aims:

* To determine the percentage of lipid clinic attendees interested in making a serious dietary change.
* To determine the extent to which a self selected dietary portfolio combining viscous fiber foods (oat \& barley β-glucan, psyllium, etc.), soy and vegetable protein foods (soy milk, soy meat analogues and almonds) and plant sterols (sterol margarine) in the same diet be significantly more effective in reducing LDL-cholesterol and other markers of cardiovascular disease risk than conventional dietary advice.
* To determine whether this effect can be maximized by more frequent follow-up, and what, if any, would be the relationship between dietary compliance and reduction in LDL-C.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A
D: Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Practical Application, Acceptability and Effectiveness of a Portfolio Diet in Reducing Serum Cholesterol
Brief Summary: The purpose of this trial is to re-evaluate the potential role of diet in modulating cardiovascular risk factors. If potent lipid-lowering effects through novel dietary interventions can be demonstrated, then diet may again be seen as providing an alternative to drug therapy in the primary prevention of cardiovascular disease.

Aims:

* To determine the percentage of lipid clinic attendees interested in making a serious dietary change.
* To determine the extent to which a self selected dietary portfolio combining viscous fiber foods (oat \& barley β-glucan, psyllium, etc.), soy and vegetable protein foods (soy milk, soy meat analogues and almonds) and plant sterols (sterol margarine) in the same diet be significantly more effective in reducing LDL-cholesterol and other markers of cardiovascular disease risk than conventional dietary advice.
* To determine whether this effect can be maximized by more frequent follow-up, and what, if any, would be the relationship between dietary compliance and reduction in LDL-C.


Options:
A: Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written dietary recommendations | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Behavioral: Cocinar Para Su Salud Program | Intervention Type: BEHAVIORAL; Name: Cocinar Para Su Salud Program; Assigned to Arm(s): Arm B | Intervention Type: BEHAVIORAL; Name: Written dietary recommendations; Assigned to Arm(s): Arm A
C: Arm Label: Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Other: mediterranean diet | Arm Label: normocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Other: normocaloric diet | Intervention Type: OTHER; Name: mediterranean diet; Assigned to Arm(s): Mediterranean Diet | Intervention Type: OTHER; Name: normocaloric diet; Assigned to Arm(s): normocaloric diet
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Eat Smart, Live Better | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Eat Smart, Live Better; Assigned to Arm(s): Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.
Brief Summary: In this clinical trial patients with newly diagnosed focal epilepsy aged 60 years or older receive three different antiepileptic drugs in a double-blind, randomized design over a period of 58 weeks. All drugs are licensed for the treatment of epilepsy. The primary endpoint of this study will be retention rate at 58-weeks, since it reflects both efficacy and tolerability.


Options:
A: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
B: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
D: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.
Brief Summary: In this clinical trial patients with newly diagnosed focal epilepsy aged 60 years or older receive three different antiepileptic drugs in a double-blind, randomized design over a period of 58 weeks. All drugs are licensed for the treatment of epilepsy. The primary endpoint of this study will be retention rate at 58-weeks, since it reflects both efficacy and tolerability.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs
D: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.
Brief Summary: In this clinical trial patients with newly diagnosed focal epilepsy aged 60 years or older receive three different antiepileptic drugs in a double-blind, randomized design over a period of 58 weeks. All drugs are licensed for the treatment of epilepsy. The primary endpoint of this study will be retention rate at 58-weeks, since it reflects both efficacy and tolerability.


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A
C: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Low Glycemic Index Diets on Glucose Control in Non-Insulin Dependent Diabetics
Brief Summary: Large observational studies have shown cereal fiber to protect from diabetes and heart disease. Despite the success of acarbose, an α-glucosidase hydrolase inhibitor, which lowers the glycemic index of foods containing starch, sucrose and maltodextrins, the use of diets containing low glycemic index foods still remains to be established. We will therefore provide otherwise healthy individuals with type 2 diabetes intensive counseling on food selection either to improve glucose control using high cereal fiber dietary strategies or low glycemic index foods. Studies will last 6 months with bloods taken for HbA1c, glucose and blood lipids. If the study shows a benefit for either or both diets then use of high fiber and/or low glycemic index foods in the diet may provide another potential way to improve glucose control and lower cholesterol levels in non-insulin dependent diabetes.


Options:
A: Arm Label: Refined grain; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Refined grain | Arm Label: Whole grain diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole grain diet; Assigned to Arm(s): Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Refined grain; Assigned to Arm(s): Refined grain
B: Arm Label: Wholegrain cereal oats; Type: EXPERIMENTAL; Interventions: Dietary Supplement: wholegrain cereals oats (WGO) | Arm Label: Non wholegrain cereals; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Non wholegrain cereals | Intervention Type: DIETARY_SUPPLEMENT; Name: wholegrain cereals oats (WGO); Assigned to Arm(s): Wholegrain cereal oats | Intervention Type: DIETARY_SUPPLEMENT; Name: Non wholegrain cereals; Assigned to Arm(s): Non wholegrain cereals
C: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
D: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: diet group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 50g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Arm Label: 100g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Intervention Type: DIETARY_SUPPLEMENT; Name: organic naked oat with whole germ (ONOG); Assigned to Arm(s): 100g-ONOG plus diet group, 50g-ONOG plus diet group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Low Glycemic Index Diets on Glucose Control in Non-Insulin Dependent Diabetics
Brief Summary: Large observational studies have shown cereal fiber to protect from diabetes and heart disease. Despite the success of acarbose, an α-glucosidase hydrolase inhibitor, which lowers the glycemic index of foods containing starch, sucrose and maltodextrins, the use of diets containing low glycemic index foods still remains to be established. We will therefore provide otherwise healthy individuals with type 2 diabetes intensive counseling on food selection either to improve glucose control using high cereal fiber dietary strategies or low glycemic index foods. Studies will last 6 months with bloods taken for HbA1c, glucose and blood lipids. If the study shows a benefit for either or both diets then use of high fiber and/or low glycemic index foods in the diet may provide another potential way to improve glucose control and lower cholesterol levels in non-insulin dependent diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
B: Arm Label: low glycemic index, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: low glycemic diet instruction | Arm Label: high cereal fibre, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: high cereal fibre diet instruction | Intervention Type: DIETARY_SUPPLEMENT; Name: low glycemic diet instruction; Assigned to Arm(s): low glycemic index, diabetic diet | Intervention Type: DIETARY_SUPPLEMENT; Name: high cereal fibre diet instruction; Assigned to Arm(s): high cereal fibre, diabetic diet
C: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
D: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks
Brief Summary: The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.


Options:
A: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
B: Arm Label: BCX7353 110 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: BCX7353 150 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 110 mg once daily, BCX7353 150 mg once daily | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): Placebo
C: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
D: Arm Label: SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Arm Label: SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Intervention Type: BIOLOGICAL; Name: CINRYZE with rHuPH20; Assigned to Arm(s): SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2, SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Rheumatoid Arthritis With Roxithromycin
Brief Summary: The purpose of this study is to evaluate the clinical efficacy, safety, and tolerability of roxithromycin in patients with rheumatoid arthritis.


Options:
A: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Roxithromycin; Assigned to Arm(s): N/A
D: Arm Label: erythromycin; Type: EXPERIMENTAL; Interventions: Drug: Erythromycin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): erythromycin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Comparison of Continuous Positive Airway Pressure (CPAP) With Standard Treatment in Out-of-hospital Patients With Acute Cardiogenic Pulmonary Edema.
Brief Summary: Evaluate efficacy and safety of CPAP in a randomised standard treatment controlled study, in out-of-hospital patients with acute cardiogenic pulmonary edema.


Options:
A: Arm Label: CPAP; Type: EXPERIMENTAL; Interventions: Procedure: CPAP | Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): standard medical therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Total face mask (interface for NPPV) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Comfort full or RT040 oronasal mask (interface for NPPV) | Intervention Type: DEVICE; Name: Total face mask (interface for NPPV); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Comfort full or RT040 oronasal mask (interface for NPPV); Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: CPAP and Non Invasive Ventilation; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: usual care of acute pulmonary oedema | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Continuous Positive Airway Pressure (CPAP) | Intervention Type: PROCEDURE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: usual care of acute pulmonary oedema; Assigned to Arm(s): A

Answer: A